Advances in non-dopaminergic treatments for Parkinson's disease

Stayte, S; Vissel, B

Advances in non-dopaminergic treatments for Parkinson's disease

Stayte, S

Vissel, B

Permalink

Publication Type:: Journal Article
Citation:: Frontiers in Neuroscience, 2014, (8 MAY)
Issue Date:: 2014-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published VersionAdobe PDF (1.05 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Stayte, S https://orcid.org/0000-0002-6518-1979	en_US
dc.contributor.author	Vissel, B https://orcid.org/0000-0001-8860-8050	en_US
dc.date.available	2014-04-30	en_US
dc.date.issued	2014-01-01	en_US
dc.identifier.citation	Frontiers in Neuroscience, 2014, (8 MAY)	en_US
dc.identifier.issn	1662-4548	en_US
dc.identifier.uri	http://hdl.handle.net/10453/75025
dc.description.abstract	Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has resulted in extensive efforts to develop new therapies that work in ways other than restoring or replacing dopamine. Here we describe newly emerging non-dopaminergic therapeutic strategies for PD, including drugs targeting adenosine, glutamate, adrenergic, and serotonin receptors, as well as GLP-1 agonists, calcium channel blockers, iron chelators, anti-inflammatories, neurotrophic factors, and gene therapies. We provide a detailed account of their success in animal models and their translation to human clinical trials. We then consider how advances in understanding the mechanisms of PD, genetics, the possibility that PD may consist of multiple disease states, understanding of the etiology of PD in non-dopaminergic regions as well as advances in clinical trial design will be essential for ongoing advances. We conclude that despite the challenges ahead, patients have much cause for optimism that novel therapeutics that offer better disease management and/or which slow disease progression are inevitable. © 2014 Stayte and Vissel.	en_US
dc.relation.ispartof	Frontiers in Neuroscience	en_US
dc.relation.isbasedon	10.3389/fnins.2014.00113	en_US
dc.title	Advances in non-dopaminergic treatments for Parkinson's disease	en_US
dc.type	Journal Article
utslib.citation.volume	8 MAY	en_US
utslib.for	1109 Neurosciences	en_US
utslib.for	1701 Psychology	en_US
utslib.for	1702 Cognitive Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access
pubs.issue	8 MAY	en_US
pubs.publication-status	Published	en_US

Abstract:

Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has resulted in extensive efforts to develop new therapies that work in ways other than restoring or replacing dopamine. Here we describe newly emerging non-dopaminergic therapeutic strategies for PD, including drugs targeting adenosine, glutamate, adrenergic, and serotonin receptors, as well as GLP-1 agonists, calcium channel blockers, iron chelators, anti-inflammatories, neurotrophic factors, and gene therapies. We provide a detailed account of their success in animal models and their translation to human clinical trials. We then consider how advances in understanding the mechanisms of PD, genetics, the possibility that PD may consist of multiple disease states, understanding of the etiology of PD in non-dopaminergic regions as well as advances in clinical trial design will be essential for ongoing advances. We conclude that despite the challenges ahead, patients have much cause for optimism that novel therapeutics that offer better disease management and/or which slow disease progression are inevitable. © 2014 Stayte and Vissel.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/75025